Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT02718898) looked at a medicine called ixekizumab (given as an 80mg injection every two weeks) compared to a placebo (a dummy treatment with no active ingredient) in people with genital psoriasis. A total of 149 people started the blinded portion of the trial — 74 received placebo and 75 received ixekizumab. The trial then moved into an open-label phase (where everyone knew what treatment was being given) and a follow-up period. The main thing being measured was how many participants' genital psoriasis was rated by a doctor as either "clear" or "minimal" by the end of the blinded treatment period. The reported data shows that, for the primary measure — a doctor's rating of genital psoriasis as "clear" or "minimal" — 55 out of 75 participants in the ixekizumab group reached that rating, compared to 6 out of 74 in the placebo group. For the secondary measures, the reported data shows: 55 ixekizumab participants versus 2 placebo participants had their overall body psoriasis rated "clear" or "minimal"; 37 versus 5 reported at least a 3-point improvement in genital itch on a 0–10 scale; 29 versus 9 reported their sexual activity was "never" or "rarely" limited by their genital psoriasis; and 23 versus 9 reported they "never" or "rarely" avoided sexual activity because of it. For quality of life (measured on a 0–30 scale where higher scores mean worse quality of life), the ixekizumab group reported an average decrease of 9.7 points from their starting score, while the placebo group reported an average decrease of 1.4 points. It is important to note that these numbers describe what was measured and counted in this specific group of trial participants — they do not tell us about longer-term outcomes, and the trial design changed across its different phases. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Psoriasis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with chronic plaque psoriasis for at least 6 months before the study starts.
- You have moderate-to-severe psoriasis in the genital area at the time of screening and at the start of the study.
- You also have plaque psoriasis somewhere on your body outside of the genital area at the time of screening and at the start of the study.
- You have already tried at least one cream, ointment, or other topical (applied to skin) treatment for psoriasis in the genital area, and it either did not work or you could not tolerate it.
- You agree to use a reliable form of birth control, which can include not having sex, throughout the study and for at least 12 weeks after your last dose of the study drug.
Who may not be able to join:
- You have a type of psoriasis other than plaque psoriasis, such as pustular, erythrodermic, or guttate psoriasis.
- Your psoriasis was caused by a medication you have taken.
- You have recently received certain psoriasis treatments (the waiting period varies depending on the treatment, ranging from 4 weeks to up to 12 months — confirm with trial site).
- You have ever been treated with ixekizumab, secukinumab, brodalumab, or a similar type of medication.
- You are unable to avoid excessive sun exposure or tanning beds for at least 4 weeks before the study starts and during the study.
- You are currently taking part in another clinical trial that involves an experimental treatment.
- You have a serious illness or medical condition other than plaque psoriasis.
- You have had or currently have a cancer diagnosis within the past 5 years before the study starts.
- You have had a serious infection in the last 3 months.
- You have received a live vaccine in the 3 months before the study starts, or plan to receive one during the study.
- You have received a BCG vaccination (a vaccine typically given for tuberculosis) within the past year.
- You are currently pregnant or breastfeeding.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
4 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Number of Participants Achieving Static Physician Global Assessment (sPGA) of Genitalia (0,1)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.